La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhejiang Huahai Pharmaceutical Crescita futura

Future criteri di controllo 4/6

Zhejiang Huahai Pharmaceutical prevede che gli utili e i ricavi cresceranno rispettivamente di 25.1% e 15.2% all'anno. Si prevede che l'EPS crescerà di 25% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 17.3% in 3 anni.

Informazioni chiave

24.6%

Tasso di crescita degli utili

24.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	19.4%
Tasso di crescita dei ricavi	15.1%
Rendimento futuro del capitale proprio	17.4%
Copertura analitica	Low
Ultimo aggiornamento	03 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 20

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Mar 22

Previsioni di crescita degli utili e dei ricavi

SHSE:600521 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	13,297	1,937	N/A	3,650	2
12/31/2025	11,761	1,648	N/A	1,067	3
12/31/2024	10,102	1,316	N/A	1,941	1
6/30/2024	9,143	1,010	1,173	2,624	N/A
3/31/2024	8,748	928	1,139	2,696	N/A
12/31/2023	8,309	830	625	2,217	N/A
9/30/2023	8,635	1,095	116	2,096	N/A
6/30/2023	8,736	1,169	-531	1,643	N/A
3/31/2023	8,552	1,203	-772	1,515	N/A
12/31/2022	8,266	1,168	-1,074	1,243	N/A
9/30/2022	7,884	692	-1,482	857	N/A
6/30/2022	7,432	540	-1,648	1,015	N/A
3/31/2022	6,919	370	-1,514	975	N/A
12/31/2021	6,644	488	-1,496	938	N/A
9/30/2021	6,212	679	-994	1,068	N/A
6/30/2021	6,215	867	-285	1,341	N/A
3/31/2021	6,412	964	-282	1,265	N/A
12/31/2020	6,485	930	279	1,555	N/A
9/30/2020	6,247	898	546	1,670	N/A
6/30/2020	6,041	813	858	1,774	N/A
3/31/2020	5,760	655	1,054	1,877	N/A
12/31/2019	5,388	570	960	1,754	N/A
9/30/2019	5,263	364	391	1,340	N/A
6/30/2019	5,209	213	-280	740	N/A
3/31/2019	5,055	81	-538	560	N/A
12/31/2018	5,095	108	-1,057	68	N/A
9/30/2018	5,335	409	-630	506	N/A
6/30/2018	5,190	573	-396	644	N/A
3/31/2018	5,112	661	N/A	518	N/A
12/31/2017	5,002	639	N/A	646	N/A
9/30/2017	4,680	601	N/A	222	N/A
6/30/2017	4,460	537	N/A	231	N/A
3/31/2017	4,254	519	N/A	306	N/A
12/31/2016	4,093	501	N/A	433	N/A
9/30/2016	4,001	492	N/A	453	N/A
6/30/2016	3,848	466	N/A	325	N/A
3/31/2016	3,738	464	N/A	238	N/A
12/31/2015	3,500	442	N/A	195	N/A
9/30/2015	3,201	399	N/A	262	N/A
6/30/2015	3,071	372	N/A	262	N/A
3/31/2015	2,793	313	N/A	258	N/A
12/31/2014	2,585	266	N/A	329	N/A
9/30/2014	2,406	277	N/A	217	N/A
6/30/2014	2,220	265	N/A	419	N/A
3/31/2014	2,224	310	N/A	433	N/A
12/31/2013	2,296	359	N/A	490	N/A
9/30/2013	2,295	404	N/A	496	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 600521 ( 25.1% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 600521 ( 25.1% all'anno) cresceranno più rapidamente del mercato CN ( 21.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 600521 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 600521 ( 15.2% all'anno) crescerà più rapidamente del mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 600521 ( 15.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 600521 sarà basso tra 3 anni ( 17.3 %).

Zhejiang Huahai Pharmaceutical Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates increase by 14%

Price target increased by 11% to CN¥18.17

Consensus revenue estimates fall by 10%

Price target decreased by 11% to CN¥17.60

Consensus EPS estimates fall by 13%

Price target decreased by 10% to CN¥20.63

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in 2Q 2023)

Consensus EPS estimates increase by 14%

Dividend reduced to CN¥0.20

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Price target increased by 11% to CN¥18.17

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.57 (vs CN¥0.81 in FY 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Investor sentiment improves as stock rises 17%

Consensus revenue estimates fall by 10%

Price target decreased by 11% to CN¥17.60

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 100 million worth of its shares.

Consensus EPS estimates fall by 13%

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.16 in 3Q 2022)

Price target decreased by 10% to CN¥20.63

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.34 in FY 2021)

Consensus EPS estimates increase by 11%

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.053 in 3Q 2021)

Price target increased to CN¥18.00

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.17 in 2Q 2021)

Zhejiang Huahai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.56 billion in funding

Price target increased to CN¥15.50

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Price target increased to CN¥15.50

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥15.50

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.24 in 2Q 2020)

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 200 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.15 in 1Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.41 in FY 2019)

New 90-day low: CN¥28.88

Market bids up stock over the past week

Third quarter 2020 earnings released: EPS CN¥0.18

New 90-day low: CN¥31.49

Price target raised to CN¥12.27

Third quarter earnings released

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020

Analysts update estimates

New 90-day low: CN¥31.92

First half earnings released

New 90-day high - CN¥44.83

New 90-day high - CN¥41.96

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita